Achieve Life Sciences Reports Q4 2024 Financial Results
Key Updates on Cytisinicline
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a leading pharmaceutical company noted for its commitment to addressing global nicotine addiction, has shared its financial results for the fourth quarter of year-end 2024, along with significant updates regarding its Cytisinicline program. The company is on track to submit its New Drug Application (NDA) for Cytisinicline at the end of the second quarter of 2025.
Recent Milestones Achieved
There are several advancements listed by the company that highlight its ongoing commitment to the Cytisinicline program. The ORCA-OL clinical trial, which focuses on long-term exposure to Cytisinicline, has successfully completed enrollment with 479 participants across 29 sites in the U.S. This study is not only vital for the overall safety profile of Cytisinicline but also essential for the NDA submission process.
Positive Outcomes in Clinical Trials
The clinical trial also achieved a significant requirement by having over 300 participants complete six months of cumulative treatment with Cytisinicline, meeting the FDA's criteria for NDA submission. The Data Safety Monitoring Committees reported positive results after thorough reviews of safety data, confirming that there are no unexpected treatment-related adverse effects.
New Leadership Enhancements
The company continues to build a robust leadership team by appointing Dr. Kristen Slaoui and Nancy Phelan to the Board of Directors. Both bring invaluable experience in corporate strategy and healthcare innovation, ensuring the organization's strength as it navigates towards NDA submission and commercialization efforts for Cytisinicline.
Chief Financial Officer Appointment
Mark Oki has taken on the role of Chief Financial Officer at Achieve, overseeing the financial operations as well as investor relations which are crucial for advancing the Cytisinicline project.
Financial Insights
As of December 31, 2024, Achieve Life Sciences reported cash, cash equivalents, and marketable securities totaling $34.4 million. The total operating expenses for the quarter were reported at $12.2 million, with a total net loss for the year at $39.8 million. These figures indicate the company's ongoing investments and strategic focus toward reaching critical development milestones.
Future Initiatives
In agreement with the FDA, Achieve has had a successful End-of-Phase 2 meeting confirming their plan to move forward with the Phase 3 study design. The company is expected to initiate the ORCA-V2 trial aimed at vaping cessation if funding becomes available within the first half of 2026.
About Achieve Life Sciences, Inc.
Achieve Life Sciences is uniquely positioned to tackle the ongoing public health crisis of nicotine addiction, with Cytisinicline being a plant-based treatment option that addresses both smoking and vaping cessation. The company has completed two Phase 3 studies for smoking cessation and one Phase 2 study for vaping cessation, reinforcing its commitment to improving public health.
Frequently Asked Questions
What are the recent developments for Achieve Life Sciences?
Achieve Life Sciences reported positive milestones in its Cytisinicline program, including successful clinical trial outcomes and new leadership appointments.
What is Cytisinicline used for?
Cytisinicline is developed for nicotine dependence treatment, specifically for aiding in smoking cessation and vaping cessation.
What are Achieve Life Sciences' financial results for 2024?
The company reported cash resources of $34.4 million and total operating expenses of $39.1 million.
How has the company been performing in terms of clinical trials?
The company has successfully enrolled participants and completed significant phases in its clinical trials aimed at ensuring the safety and efficacy of Cytisinicline.
What does the future hold for Achieve Life Sciences?
The company plans to submit its NDA for Cytisinicline by Q2 2025 and will continue to focus on advancing its clinical trials.
